Moderna, Inc. - Common Stock (MRNA)
248.69
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 12th, 7:47 AM EST
News & Press Releases
Moderna Outlines Next Phase of Growth at Analyst Day
Highlights intismeran and cancer antigen therapies as foundational opportunities for a growing oncology franchiseDetails commercial and manufacturing readiness for intismeran following positive Phase 3 results in adjuvant melanomaHighlights multiple levers to improve infectious disease vaccine franchise profitabilityOutlines mid-term financial strategy focused on growth and disciplined capital allocation
By Moderna, Inc. · Via ACCESS Newswire · November 12, 2026
S&P 500 Top Movers Today: Double-Digit Gainers Lead, Declines Stay Smallerchartmill.com
Via Chartmill · November 11, 2026
Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
Real-world analysis of more than 294,000 U.S. Veterans aged 65 and older found mNEXSPIKE was associated with a 35.9% lower risk of medically attended COVID-19 and a 47% lower risk of COVID-19-associated hospitalization versus Comirnaty (COVID-19 Vaccine, mRNA)
By Moderna, Inc. · Via ACCESS Newswire · November 11, 2026
Moderna (NASDAQ:MRNA) Q3 Earnings Beat and Raised Guidance Fuel Stock Rallychartmill.com
Via Chartmill · November 6, 2026
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boommarketbeat.com
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via MarketBeat · November 11, 2026
S&P 500 Top Gainers and Losers for Today's Sessionchartmill.com
Via Chartmill · November 10, 2026
S&P 500 Gap-Down Stocks: Nov. 10, 2026 Sessionchartmill.com
Via Chartmill · November 10, 2026
Moderna to Present at Upcoming Conference in November 2026
CAMBRIDGE, MA / ACCESS Newswire / November 10, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:
By Moderna, Inc. · Via ACCESS Newswire · November 10, 2026
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buyfool.com
Revenue for the vaccine maker rose sharply in the third quarter, but it was largely due to COVID sales, which have been down significantly over the past five years.
Via The Motley Fool · November 9, 2026
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027fool.com
Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.
Via The Motley Fool · November 9, 2026
Stock Market Today: Nvidia Board Opens Probe Into Jensen Huang as Wall Street Licks Its AI Woundschartmill.com
Via Chartmill · November 9, 2026
Moderna: 3 Key Takeaways for Long-Term Investorsfool.com
Its proprietary software is built into the cancer drug itself, creating a front-end design moat that rivals may struggle to replicate.
Via The Motley Fool · November 8, 2026
The 5 most interesting analyst questions from Moderna’s Q3 2026 earnings call
Moderna’s third quarter was marked by robust revenue growth, operational improvements, and a positive market response. Management attributed the strong resul...
Via StockStory · November 8, 2026
MRNA Q3 2026 deep dive: oncology data, pipeline milestones, and international growth reshape outlook
Biotechnology company Moderna (NASDAQ:MRNA) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 29.2% year on year to $1.31 b...
Via StockStory · November 7, 2026
Why is Moderna (MRNA) stock soaring today
What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after the company reported third-quarter 2026 finan...
Via StockStory · November 6, 2026
Moderna (MRNA) Q3 2026 Earnings Call Transcriptfool.com
Profitability returned as international partnerships offset a norovirus setback.
Via The Motley Fool · November 6, 2026
S&P 500 Top Movers: Nov. 6, 2026 Gainers and Loserschartmill.com
Via Chartmill · November 6, 2026
What Moderna (MRNA) Said on Its Q3 Earnings Callmarketbeat.com
Moderna (NASDAQ:MRNA) raised its 2026 revenue growth outlook after reporting higher third-quarter sales and a return to quarterly profitability, as demand for its COVID-19 vaccines and international partnerships supported results.
The company reported revenue of $1.3 billion, up 29% from a year ear
Via MarketBeat · November 6, 2026
Moderna Just Gave Investors Yet Another Thing to Cheer Aboutfool.com
Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is improving, too.
Via The Motley Fool · November 6, 2026
Moderna (NASDAQ:MRNA) delivers strong Q3 2026 numbers, stock soars
Biotechnology company Moderna (NASDAQ:MRNA) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 29.2% year on year to $1.31 b...
Via StockStory · November 6, 2026
Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38Increases 2026 expected revenue growth to 15%-25%, exceeding the previous expectation of up to 10% growthImproves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimateIncreases 2026 expected ending cash balance to $8.1-$8.3 billionHighlights positive Phase 3 data for intismeran and U.S. FDA approval of mFLUSIVA, the Company's fifth approved product globally
By Moderna, Inc. · Via ACCESS Newswire · November 6, 2026
Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU®
By Moderna, Inc. · Via ACCESS Newswire · November 5, 2026
S&P 500 After-Hours Movers: ABNB and SNDK Gain, AXON and SOLV Fallchartmill.com
Via Chartmill · November 5, 2026
Moderna (MRNA) Q3 earnings report preview: what to look for
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting earnings this Friday before market hours. Here’s what to expect. Moderna beat analysts’ revenue...
Via StockStory · November 4, 2026
Universal Health Services, Tenet Healthcare, Moderna, Novavax, and Intuitive Surgical stocks trade up, what you need to know
What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...
Via StockStory · November 4, 2026